Search Results
You are looking at 1 - 3 of 3 items for
- Author: Jaydira Del Rivero x
- Refine by access: All content x
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Josh Mailman in
Google Scholar
PubMed
Search for other papers by Michael W Rabow in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by Sarah Creed in
Google Scholar
PubMed
Search for other papers by Hagen F Kennecke in
Google Scholar
PubMed
Search for other papers by Janice Pasieka in
Google Scholar
PubMed
Search for other papers by Jennifer Zuar in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
This serves as a white paper by the North American Neuroendocrine Tumor Society (NANETS) on the practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. The authors involved in the development of this manuscript represent a multidisciplinary team of patient advocacy, palliative care, and hospice care practitioners, endocrinologist, and oncologists who performed a literature review and provided expert opinion on a series of questions often asked by our patients and patient caregivers affected by this disease. We hope this document serves as a starting point for oncologists, palliative care teams, hospice medical teams, insurers, drug manufacturers, caregivers, and patients to have a frank, well-informed discussion of what a patient needs to maximize the quality of life during a routine, disease-directed care as well as at the end-of-life.
Search for other papers by Adel Mandl in
Google Scholar
PubMed
Search for other papers by James M Welch in
Google Scholar
PubMed
Search for other papers by Gayathri Kapoor in
Google Scholar
PubMed
Search for other papers by Vaishali I Parekh in
Google Scholar
PubMed
Search for other papers by David S Schrump in
Google Scholar
PubMed
Search for other papers by R Taylor Ripley in
Google Scholar
PubMed
Search for other papers by Mary F Walter in
Google Scholar
PubMed
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Smita Jha in
Google Scholar
PubMed
Search for other papers by William F Simonds in
Google Scholar
PubMed
Search for other papers by Robert T Jensen in
Google Scholar
PubMed
Search for other papers by Lee S Weinstein in
Google Scholar
PubMed
Search for other papers by Jenny E Blau in
Google Scholar
PubMed
Search for other papers by Sunita K Agarwal in
Google Scholar
PubMed
Patients with the multiple endocrine neoplasia type 1 (MEN1) syndrome carry germline heterozygous loss-of-function mutations in the MEN1 gene which predisposes them to develop various endocrine and non-endocrine tumors. Over 90% of the tumors show loss of heterozygosity (LOH) at chromosome 11q13, the MEN1 locus, due to somatic loss of the wild-type MEN1 allele. Thymic neuroendocrine tumors (NETs) or thymic carcinoids are uncommon in MEN1 patients but are a major cause of mortality. LOH at the MEN1 locus has not been demonstrated in thymic tumors. The goal of this study was to investigate the molecular aspects of MEN1-associated thymic tumors including LOH at the MEN1 locus and RNA-sequencing (RNA-Seq) to identify genes associated with tumor development and potential targeted therapy. A retrospective chart review of 294 patients with MEN1 germline mutations identified 14 patients (4.8%) with thymic tumors (12 thymic NETs and 2 thymomas). LOH at the MEN1 locus was identified in 10 tumors including the 2 thymomas, demonstrating that somatic LOH at the MEN1 locus is also the mechanism for thymic tumor development. Unsupervised principal component analysis and hierarchical clustering of RNA-Seq data showed that thymic NETs formed a homogenous transcriptomic group separate from thymoma and normal thymus. KSR2 (kinase suppressor of Ras 2), that promotes Ras-mediated signaling, was abundantly expressed in thymic NETs, a potential therapeutic target. The molecular insights gained from our study about thymic tumors combined with similar data from other MEN1-associated tumors may lead to better surveillance and treatment of these rare tumors.
Search for other papers by Roland Därr in
Google Scholar
PubMed
Search for other papers by Joan Nambuba in
Google Scholar
PubMed
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Ingo Janssen in
Google Scholar
PubMed
Search for other papers by Maria Merino in
Google Scholar
PubMed
Search for other papers by Milena Todorovic in
Google Scholar
PubMed
Search for other papers by Bela Balint in
Google Scholar
PubMed
1st Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovakia
Search for other papers by Ivana Jochmanova in
Google Scholar
PubMed
Search for other papers by Josef T Prchal in
Google Scholar
PubMed
Search for other papers by Ronald M Lechan in
Google Scholar
PubMed
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by Vera Popovic in
Google Scholar
PubMed
Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Search for other papers by Karen T Adams in
Google Scholar
PubMed
Search for other papers by F Ryan Prall in
Google Scholar
PubMed
Search for other papers by Alexander Ling in
Google Scholar
PubMed
Search for other papers by Meredith R Golomb in
Google Scholar
PubMed
Search for other papers by Michael Ferguson in
Google Scholar
PubMed
Search for other papers by Naris Nilubol in
Google Scholar
PubMed
Search for other papers by Clara C Chen in
Google Scholar
PubMed
Search for other papers by Emily Chew in
Google Scholar
PubMed
Search for other papers by David Taïeb in
Google Scholar
PubMed
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
Search for other papers by Tito Fojo in
Google Scholar
PubMed
Search for other papers by Chunzhang Yang in
Google Scholar
PubMed
Search for other papers by Electron Kebebew in
Google Scholar
PubMed
Search for other papers by Zhengping Zhuang in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings into perspective these experiences with the pertinent literature. Six females and one male presented at a median age of 28 years (range 11–46). Two were found to have HIF2A somatic mosaicism. No relatives were affected. All patients were diagnosed with polycythemia before age 8 and before PGL/SOM developed. PGLs were found at a median age of 17 years (range 8–38) and SOMs at 29 years (range 22–38). PGLs were multiple, recurrent and metastatic in 100, 100 and 29% of all cases, and SOMs in 40, 40 and 60%, respectively. All PGLs were primarily norepinephrine-producing. All patients had abnormal ophthalmologic findings and those with SOMs had gallbladder disease. Computed tomography (CT) and magnetic resonance imaging revealed cystic lesions at multiple sites and hemangiomas in 4 patients (57%), previously thought to be pathognomonic for von Hippel–Lindau disease. The most accurate radiopharmaceutical to detect PGL appeared to be [18F]-fluorodihydroxyphenylalanine ([18F]-FDOPA). Therefore, [18F]-FDOPA PET/CT, not [68Ga]-(DOTA)-[Tyr3]-octreotate ([68Ga]-DOTATATE) PET/CT is recommended for tumor localization and aftercare in this syndrome. The long-term prognosis of the syndrome is unknown. However, to date no deaths occurred after 6 years follow-up. Physicians should be aware of this unique syndrome and its diagnostic and therapeutic challenges.
